It refers to the antibody connecting to Step-1, including a variable heavy chain region (VH), including a seq-1 HCB, a seq-2 HCB, a seq-2 HCB and a seq-3 HCB 4, 5 and 6 HCB, as well as a variable light chain region (VL), including a seq-7 LCDR 1, a seq-8 LCDR 2. This is intelligence 9's LCDR 3 This antibody is anti degradable It also refers to the polymer molecules binding to the first antigen: Step-1 in the target cell； and the second antigen: CD3 as the T-lymphocyte active antigen, in which the antibody binds to both targets at the same time.Forcing the short-term interaction between target cells and T lymphocytes, leading to the activity of any cellular T lymphocytes, and leading to target cell failure, is an effective way to treat cancer. It also refers to the polynucleotide encoded by the antibody； one or more vectors, especially an expression vector； a host cell containing the polynucleotide； a process of producing the antibody； and a drug synthesis including the antibody.Se refiere a un anticuerpo que se une a STEAP-1, el cual comprende una region variable de cadena pesada (VH) que comprende una HCDR 1 de la SEQ ID NO: 1, una HCDR 2 de la SEQ ID NO: 2 y una HCDR 3 de la SEQ ID NO: 4, 5 y 6, y una region variable de cadena ligera (VL) que comprende una LCDR 1 de la SEQ ID NO: 7, una LCDR 2 de la SEQ ID NO: 8, una LCDR 3 de la SEQ ID NO: 9. Dicho anticuerpo es resistente a la degradacion. Asimismo, se refiere a moleculas de union a antigeno biespecificas que se unen a un primer antigeno: STEAP-1 en celulas diana； y a un segundo antigeno: CD3 como un antigeno activador de linfocitos T； donde la union simultanea del anticuerpo a sus dos dianas, forzara a una interaccion temporal entre la celula diana y el linfocito T, provocando la activacion de cualquier linfocito T citotoxico y la posterior lisis de la celula diana, siendo util en el tratamiento de cancer. Tambien se refiere a polinucleotidos que codifican dicho anticuerpo； uno o mas vectores, en particular un
